Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... from Takamatsu, Japan, "Recent studies indicate a role of chymase in the regulation of angiotensin II (AngII) formation in cardiovascular and renal tissues. We investigated a possible ... acid (50 mg/kg, twice a day, p.o.), or the selective AT(1)-receptorblocker olmesartan (10 mg/kg per day, p.o.) for 14 days. UUO-induced renal interstitial ...
2009 NOV 2 ... Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptorblocker (ARB) Micardis=AE (telmisartan) Tablets 80 mg for reduction of the ...
2009 NOV 9 ... as risk factors for CVD." "To investigate the possible involvement of the angiotensin system, an angiotensin II receptor antagonist, candesartan cilexetil, or a nonspecific ... and colleagues published their study in Reproductive Sciences (Angiotensin II Receptor Blocker Candesartan Cilexetil, but Not Hydralazine Hydrochloride, Protects Against Mouse Cardiac ...
2009 NOV 16 ... "Whether the use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker inhibitor (ACEI/ARB) is beneficial in renal transplant recipients remains controversial. ...
2009 NOV 30 ... early feedback group after the public release of the report card. "The absolute rate of angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptorblocker use in patients ...
2009 NOV 9 ... the effects between calcium channel blockers and diuretics when used in combination with angiotensin II receptorblocker on aortic systolic blood pressure (BP) and brachial ambulatory ...
2009 NOV 9 ... is deposition of amyloid-beta protein (A beta) in the brain. Telmisartan is a unique angiotensin II receptorblocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ...
2009 NOV 30 ... their study in Circulation (Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to ...
2009 NOV 23 ... and more likely to have a nonischemic etiology and a higher ejection fraction. Dose of angiotensin converting enzyme inhibitor (ACEI) was lower in the women, on average. The lower ACEI ... the women, on average. The lower ACEI dose may reflect the higher use of angiotensin II receptorblocker (ARB) in women. Both the peak VO2 and the 6-minute walk distance were ...
2009 NOV 9 ... Mehta and colleagues published their study in Clinical Cardiology (Angiotensin Receptor Blocker Therapy for Heart Failure Patients: Is Combination Treatment a Feasible Prospect? ...
2009 NOV 30 ... The mean age of the patients was 80 +/- 7.8 years; 46% were male; 64% were receiving an angiotensin-converting enzyme inhibitor, 34% an angiotensin-II receptorblocker, and 68% were ...
2009 NOV 16 ... a bundle of fixed doses of a generic statin and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), delivered with minimal outpatient visits, laboratory testing, and dosage ...
2009 NOV 16 ... is a serious problem with a high risk of graft loss. The therapeutic role of renin-angiotensin-system (RAS) blockers in recurrent FSGS is not clear." "We present the ... safety and efficacy of an intensified triple RAS blockade with an ACE-inhibitor, an AT 1 receptorblocker and the direct renin inhibitor aliskiren in a 29-year-old renal transplant ...
2009 NOV 23 ... "Several studies have implicated the renin angiotensin system in the cardiac hypertrophy induced by thyroid hormone. However, whether ... the cardiac hypertrophy induced by thyroid hormone. However, whether Angiotensin type 1 receptor (AT(1)R) is critically required to the development of T-3-induced cardiomyocyte ... questions, we employed a selective small interfering RNA (siRNA, 50 nM) or an AT(1)R blocker (Losartan, 1 mc M) to evaluate the specific role of this receptor in primary cultures of ...
2009 NOV 30 ... outpatients with mild to moderate hypertension. (11 per group) received an angiotensin receptor blocker (ARB; irbesartan 300 mg/day or valsartan 160 mg/day) or an angiotensin-converting enzyme ...
2009 NOV 23 ... According to recent research from the United States, "The renin-angiotensin-aldosterone system (RAAS), an important regulator of blood pressure as well as fluid and ... RAAS with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II (ANG-II) receptor blockers (ARBs) lowers blood pressure, decreases morbidity and mortality in patients ... System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. American Journal of Hypertension, 2009;22(10):1032-1040). For ...
2009 NOV 9 ... (MMP)-9 secretion by these cells." "We investigated the effects of the angiotensin II type 1 receptor antagonist losartan and its metabolites (EXP3174 and EXP3179) on ... hypertensives compared with the other group of patients. Thus, EXP3179 acts as a blocker of the NADPH oxidase in phagocytic cells by a potential mechanism that targets the ...
2009 NOV 23 ... of the renin angiotensin system using angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blocker (ARB) drug therapies has been shown to reduce blood pressure and associated renal and ...
